Pharmacogenetics—expectations and reality

BMJ

Volumn 329, Issue 7456, 2004, Pages 4-6

  Tucker, Geoff ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AZATHIOPRINE; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; INHALATION ANESTHETIC AGENT; IRINOTECAN; MERCAPTOPURINE; NEUROLEPTIC AGENT; PROTON PUMP INHIBITOR; TRASTUZUMAB; TRICYCLIC ANTIDEPRESSANT AGENT; WARFARIN;

ALGORITHM; BEHAVIOR; BLEEDING; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BREAST CANCER; CARDIOTOXICITY; CONFUSION; COST BENEFIT ANALYSIS; DEMOGRAPHY; DIARRHEA; DRUG INDUSTRY; DRUG MONITORING; DRUG RESPONSE; ECONOMIC ASPECT; EDITORIAL; ENVIRONMENTAL FACTOR; EXTRAPYRAMIDAL SYMPTOM; GENOMICS; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALIGNANT HYPERTHERMIA; PHARMACOGENETICS; PRIORITY JOURNAL; SIDE EFFECT; TARDIVE DYSKINESIA; TREATMENT FAILURE;

DRUG INTERACTIONS; GENETIC TECHNIQUES; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS;

EID: 3042728674     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.329.7456.4     Document Type: Editorial

References (10)

1. Smith SE, Rawlins MD. Variability in human drug response. London: Butter-worths, 1973.
2. Vogel CL, Cobleigh MA, Tripathy D, Debu G, Harris JC, Lyndsay N, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719–26.
3. Hetherington S, Hughes AR, Mosteller M, Shortino D, Baker KL, Spreen W, et al. Genetic variations in HLS-B region and hypersensitivity reactions to abacavir. Lancet 2002; 359: 1121–2.
4. Urquhart J. The odds of the three nons when an aptly prescribed medicine isn't working: non-compliance, non-absorption, non-response. Br J Clin Pharmacol 2002; 54: 212–20.
5. Food and Drug Administration. Innovation or stagnation? Challenge and opportunity on the critical path to new medical products. Washington: FDA, 2004. http://www.fda.gov/oc/initiatives/criticalpath/whitepaper.pdf (accessed 15 Jun 2004).
6. Academy of Medical Sciences. Strengthening clinical research. London: Academy of Medical Sciences, 2003. www.acmedsci.ac.uk/p_scr.pdf (accessed 15 Jun 2004).
7. Veenstra DL, Higashi MK, Phillips KA. Assessing the cost-effectiveness of pharmacogenomics. AAPS PharmSci 2000; 2: E29.
8. Gage BF, Eby C, Milligan PE, Banet GA, Duncan JR, McLeod HL. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost 2004; 91: 87–94.
9. Lee S.S.-J. Race, distributive justice and the promise of pharmacogenomics: ethical considerations. Am J Pharmacogenomics 2003; 3: 385–92.
10. Hapgood R. The potential and limitations of personalised medicine in primary care. Br J Gen Pract 2003; 53: 915–6.